Science

QRxPharma’s Dual Opioid® is based on patented discoveries at the University of Queensland. Scientists at the University postulated that the opioid oxycodone acts through a different set of neural receptors than other opioids like morphine, oxycodone or fentanyl. They also found that sub-analgesic doses of oxycodone have a synergy with sub-analgesic doses of other opioids, and therefore when combined together in low doses produce pain relief with fewer side effects and risks.

The clinical breakthrough of this patented combination is effective pain relief with a reduction in total daily opioid dose consumption. The dose related adverse effects of opioid-containing products limit their effectiveness and reduce quality of life. Side effects include respiratory depression, constipation, sedation and drowsiness, nausea and vomiting, and psychological dependence and tolerance. Fraud and abuse can also be major issues.

MoxDuo® IR (Q8003 IR) began Phase 3 clinical trials in November 2007.